7.1.4.1. active surveillance watchful waiting. elderly comorbid patients incidental srms low rcc-specific mortality significant competing-cause mortality . regard, beyond age comorbidities, frailty increasingly recognised major risk factor adverse perioperative oncological outcomes patients genitourinary malignancies. frailty geriatric syndrome characterised decline individuals’ resilience physiological functional reserve across multiple body systems, resulting increased vulnerability external stressors . comprehensive geriatric assessment considered gold standard care older patients several settings, given ability identify frailty risk geriatric syndromes positive impact patients’ outcomes. sr evaluatig impact frailty perioperative oncologic outcomes patients undergoing surgery ablation rcc found low-quality evidence pointing frailty sarcopenia potential independent risk factors worse perioperative oncological outcomes across different rcc stages. active surveillance defined initial monitoring tumour size serial abdominal imaging (us, ct, mri) delayed intervention reserved tumours showing clinical progression follow-up . concept differs concept ‘watchful waiting’; watchful waiting reserved patients whose comorbidities contra-indicate subsequent active treatment require follow-up imaging, unless clinically indicated. population-based studies compared oncological outcomes surgery (rn pn) non-surgical management tumours < 4 cm. analyses showed significantly lower csm patients treated surgery . however, patients assigned surveillance arm older likely frailer less suitable surgery. other-cause mortality rates non-surgical group significantly exceeded surgical group . analyses older patients (> 75 years) failed show benefit csm surgical treatment . growth rate metastasisin largest reported series growth renal tumours low progression metastatic disease reported limited number patients . sr eighteen cohorts comprising 2,066 patients (ct1-2 n0m0) pooled mean follow-up 53 months, showed 2.1% (95% ci: 1.0-3.6) patients developed metastatic disease follow-up . patients srms (nine studies, n = 987), pooled metastasis rate 1.8% (95% ci: 0.5-3.7). 136 biopsy-proven srms managed as, median follow-up patients remained 5.8 years (interquartile range 3.4-7.5 years). clear-cell rcc grew faster papillary type 1 srms (0.25 0.02 cm/year average, respectively, p = 0.0003). overall, 60 (44.1 %) malignant srms progressed; 49 (82%) rapid growth (volume doubling), seven (12%) increasing ≥ 4 cm, four (6.7%) criteria. six patients developed metastases, ccrcc histology . overall- cancer-specific survivala single-institutional comparative study evaluating patients aged > 75 years showed decreased os underwent surveillance nephrectomy relative nss clinically t1 renal tumours. however, multivariate analysis, management type associated os adjusting age, comorbidities, variables . statistically significant differences os css observed another study rn vs. pn vs. t1a renal masses follow-up 34 months . prospective non-randomised multi-institutional delayed intervention surveillance small renal masses (dissrm) study enrolled 497 patients solid renal masses < 4 cm selected either primary active intervention. patients selected older, worse ecog scores, comorbidities, smaller tumours, often multiple bilateral lesions. patients elected study overall median srm growth rate 0.09 cm/year median follow-up 1.83 years. growth rate variability decreased longer follow-up. patients developed metastatic disease died rcc . overall survival primary intervention 98% 96% two years, 92% 75% five years, respectively (p = 0.06). five years, css 99% 100%, respectively (p = 0.3). active surveillance predictive os css regression modelling relatively short follow-up . previously mentioned large sr eighteen cohorts 1.0% (95% ci: 0.3-2.1) died rcc 22.6% (95% ci: 15.8-30.2) died cause. patients srms rcc-specific mortality 0.6% (95% ci: 0-2.1), all-cause mortality 28.5% (95% ci: 17.4-41.4) . study using data dissrm registry investigated outcomes active surveillance cohort patients aged 60 younger diagnosis . 224 patients median follow-up 4.9 years, 30.4% chose surveillance. 20 (29.4%) surveillance progression events, including four elective crossovers, 13 (19.1%) patients underwent delayed intervention. among patients initial tumour size ≤ 2 cm, 15.1% crossed over, compared 33.3% initial tumour size 2-4 cm. overall survival similar primary intervention surveillance 7 years (94.0% vs 90.8%, log-rank p = 0.2). cancer-specific survival remained 100% groups. recurrence-free survival five years 96.0% 100% primary delayed intervention, respectively (log-rank p = 0.6). overall, short- intermediate-term oncological outcomes indicate selected patients advanced age and/or comorbidities, appropriate initially monitoring srms, followed, required, treatment progression [370,375,376,383-386]. quality lifea multicentre study assessed qol patients undergoing immediate intervention vs. as. patients undergoing immediate intervention higher qol scores baseline, specifically physical health. perceived benefit physical health persisted least one year following intervention. mental health, includes domains depression anxiety, adversely affected .